Novacyt Q&A: hear the latest from this Covid testing firm
19th August 2021 09:24
by Investor Meet Company from ii contributor
Share on
Novacyt shares rallied following the company's half-year update. Watch management discuss progress and answer investor questions.
Novacyt (LSE:NCYT) CEO Graham Mullis and his team present their half-year update and answer a range of investor questions. The event, held on the 19 August 2021, is brought to you by our friends at Investor Meet Company.
Highlights:
Q&A 38:00
About Company
Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. Its diagnostic products are used in LBC, oncology, microbiology, hematology, and serology testing. The company operates its business through the following business segments. Primerdesign is the designer, manufacturer, and marketer of molecular 'real-time' qPCR testing devices and reagents in the areas of infectious diseases based in Southampton, UK: Lab21 Product segment is a developer, manufacturer, and distributor of a large range of protein-based infectious disease IVD products; IT-IS International segment develops PCR devices for the life sciences and food testing industry and Corporate segment. Novacyt SA develops and markets solutions in medical cytology. It offers portfolio of cancer and infectious disease diagnostics products and services. It has three reportable segments: Cytology, Diagnostics and Molecular Testing.
These articles are provided for information purposes only. Occasionally, an opinion about whether to buy or sell a specific investment may be provided by third parties. The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.
Full performance can be found on the company or index summary page on the interactive investor website. Simply click on the company's or index name highlighted in the article.